BARD C R Stock Quote

$332.23 arrow  Change: -0.78 %Chge: -0.23% Vol: 91,005
End Of Day Prices
High: 333.93 | Low: 331.71 | Open: 333.55 | Close: 332.23
52 Wk High: 337.77 | 52 Wk Low: 242.03 | Todays Pivot: 332.62
Sector: Healthcare and Pharmaceuticals add stock to watch list

BCR Chart


You need Flash Player to see the chart, please download from the link below

Get Adobe Flash player

Related Healthcare and Pharmaceuticals Companies

Biomarin Pharmaceutical 89.21 green arrow 29,027
Illumina 73.83 green arrow 118,199
Steris 64.8 red arrow 106,325
Hill Rom Hldgs 28.91 green arrow 41,893
Carefusion 27.7 green arrow 207,541
Cerner 54.41 red arrow 105,453
Medtronic 72.64 green arrow 351,930
Varian Med Sys 85.975 green arrow 20,815

Above is a small selection of related companies to Bard C R which compete alongside BCR within the Healthcare and Pharmaceuticals sector. To see more related companies to BCR, view our stock market today information page.

Online News For Bard C R

C R Bard Inc (NYSE:BCR) Shares Bought by GABELLI & Co INVESTMENT ADVISERS INC.

Complete the form below to receive the latest headlines and analysts' recommendationsfor C R Bard with our free daily email newsletter: GABELLI & Co INVESTMENT ADVISERS INC. increased its stake in shares of C R Bard Inc (NYSE:BCR) by 72.4% during the 4th ...


C R Bard Inc (BCR) Receives Average Rating of “Hold” from Analysts

Shares of C R Bard Inc (NYSE:BCR) have been given an average rating of “Hold” by the eleven analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, eight have issued a ...


Are different types of BCR-ABL1 transcripts associated with different outcomes?

This study examined outcomes in chronic myeloid leukemia (CML) patients with different types of a genetic abnormality known as BCR-ABL1. While patients with the BCR-ABL transcript e14a2 showed better response to treatment, long-term outcomes were similar ...


BCR Editorial Board Roundtable

The Winter Olympics have begun. Do you plan to watch any of the coverage? What are your favorite Winter Olympics sports? Note to readers: The Bureau County Republican Editorial Board presents the BCR Editorial Board Roundtable. Members of the Editorial ...


Asciminib Drug Analysis 2016-2025: A BCR-ABL-Targeted Tyrosine Kinase Inhibitor (TKI) in Development by Novartis - ResearchAndMarkets.com

The "Drug analysis: asciminib" drug pipelines has been added to ResearchAndMarkets.com's offering. Asciminib (Novartis) is a BCR-ABL-targeted tyrosine kinase inhibitor (TKI) in development by Novartis for Philadelphia chromosome-positive diseases such as ...



Want To Add This Quote To Your Site?

With our stock widgets you can add a Bard C R quote to your website to keep your users up to date with the market. We have a variety of different styled widgets for BCR to choose from. Visit here to build your stock quote widget »